Introduction
The completion of the human genome project was a momentous occasion for humanity. It opened up the opportunity to dissect complex human traits and to understand basic pathways of health and disease. The strategies for looking at host genetic factors are varied and include linkage analysis studies that are suitable for pursuing rare high-risk alleles in conditions that have a hereditary basis. Equally, population-based association studies are very useful for examining genes with a role in commoner multifactorial diseases that have a strong environmental component (Risch, 2000) . These association studies often estimate the risk of developing a certain disease in carriers and non-carriers of a particular genetic polymorphism. The overwhelming majority of polymorphisms studied are single nucleotide polymorphisms (SNPs) that occur with a frequency of >1% in the normal population (in contrast to 'mutations' that occur with a frequency of o1%). It is estimated that up to 10 million SNPs are probably present in the human genome though not all have thus far been identified. Naturally, most of these SNPs do not occur in coding sequences, and even those that do, are not associated with any alteration in the amino acid sequence and are therefore of no functional consequence. A more useful definition of the variability of these SNPs involves haplotype analysis. Haplotypes are a combination of alleles at different markers along the same chromosome that are inherited as a unit. The HapMap project was set up to address this (www. hapmap.org) and is a valuable tool that will facilitate the study of genetic polymorphisms relevant to human health and disease. Other types of genetic variation include deletion and insertion polymorphisms and microsatellite repeat polymorphisms.
There has been an exponential rise in the number of published genetic association studies. Quite often, a report of a single genetic marker is published with great promise only to be followed by several negative studies that fail to reproduce the original observation. There is no doubt that the strategy of genetic association studies could be a powerful tool for dissecting human diseases, provided certain principles are observed to minimize the chances of false positive, and negative, reports. The most important of these principles are (1) rigorous definition of disease phenotype, (2) choice of candidate genes that are plausibly linked to the pathophysiology of the disease under study, (3) selection of polymorphisms with known (or at least potentially) functional consequences, (4) choice of genetic markers that are reasonably frequent in the population under study (variant allele frequency of at least 5%), (5) appropriate selection of controls that are matched for ethnicity, age, gender and environmental exposures, (6) design of studies that are adequately powered to produce a valid result. Even then, the statistical analyses of such studies have to take into account the real problem of false positive results by multiple testing. Appropriate corrections for multiple testing have to be applied, or alternatively, the positive findings should be regarded as preliminary and should be validated in an independent set of cases and controls. Finally, the genetic epidemiology has to involve basic science in order to unravel and validate the molecular mechanisms involved. Adherence to these basic principles will ensure that false positive trails are minimized and will offer a true opportunity to understand complex multifactorial human diseases. There has never been a more stressing time for adherence to these principles, as the advancement in genotyping technology has made possible the annotation of the entire human genome. Current technology allows us to genotype up to 500 000 SNPs in one run. We have witnessed a shift towards these so-called whole genome association studies where large multi-centre consortia attempt to examine a very large number of cases and controls for a particular disease. The power of these studies allows for an exploratory phase where thousands of SNPs are examined and a validation phase that attempts to replicate positive associations independently. More awesome is the future prospect of replacing genotyping and haplotyping with direct low-cost sequencing of the entire genome, the so-called '$1000 genome' (Collins et al., 2003) .
In this review, we attempt to shed some light on the role of genetic polymorphisms in the Toll-like receptor (TLR) genes and how this influences the risk of cancer. The basic pathobiology of these TLRs in relation to cancer has been discussed extensively in the accompanying reviews and we will concentrate on the role of variations in their genes. We will start by summarizing some of the published literature on relevant polymorphisms in some of the TLRs. We will then discuss specific examples of polymorphisms in TLRs that have been implicated in gastric and prostate cancer.
Genetic polymorphisms in Toll-like receptors
TLRs play an essential role in innate immunity, being involved in regulation of inflammatory reactions and activation of the adaptive immune response to eliminate harmful pathogens. Hundreds of SNPs have been identified in TLRs but the functional consequences of these have not been uncovered in the overwhelming majority. Many associations have been reported between TLR polymorphisms and infectious disease or cancers and as we will see later, it is the interaction between infection and chronic inflammation that most likely mediates the increased risk of cancer development. The following section discusses the better-known polymorphisms in TLR2, TLR4, TLR5 and TLR9. There are other polymorphisms described in TLR1, TLR3, TLR6 and TLR10 but these are very rare and poorly understood (see Table 1 ).
Toll-like receptor 2
SNPs in TLR2 have been reported to alter the susceptibility to various inflammatory and infectious diseases. The two most common TLR2 SNPs are Arg677Trp and Arg753Gln. The Arg677Trp mutation has been suggested to cause impaired function of the intracellular domain of the TLR2 protein (Kang and Chae, 2001 ). The impaired intracellular domain fails to interact with MyD88, which subsequently lowers the production of cytokines especially IL-2 (Kang and Chae, 2001) . The polymorphism, which causes an amino acid change from arginine to tryptophan, has been reported to be associated with lepromatous leprosy in a Korean population (Kang and Chae, 2001 ) and recurrent bacterial infections in Turkish children (Kutukculer et al., 2007) .
The other well-described TLR2 SNP is also located in the coding region, which is at amino acid position 753 substituting an arginine residue to a glutamine residue (Schroder et al., 2003) . The polymorphism has been reported to increase the risk of gram-negative sepsis in a Caucasian population (Schroder et al., 2003) . Recently, Hamann et al. (2005) showed that carriage of the Arg753Gln SNP was also a risk factor for coronary restenosis, a chronic inflammatory disease, for patients undergoing percutaneous transluminal coronary angioplasty.
In addition to these two SNPs, Jelavic et al. (2006) reported that the allele frequency of a TLR2 guaninethymine (GT) microsatellite repeat polymorphism in the second intron has an impact on the susceptibility to sporadic colorectal cancer. Individuals who developed sporadic colorectal cancer tended to have decreased frequency of alleles 20 and 21 GT repeats and increased frequency of alleles with 31 GT repeats (Jelavic et al., 2006) . Another single polymorphism within TLR2 promoter region has been identified to be associated with asthma in children (Yang et al., 2004) . The result was supported by a larger study investigating the functionality of TLR2/16934 polymorphism with asthma in children of European farmers (Eder et al., 2004) .
Toll-like receptor 4
TLR4 is required for innate immunity to gram-negative bacteria. Arbour et al. screened the entire coding region of TLR4 in 82 subjects using single-strand conformation polymorphism and direct DNA sequencing, and identified a common SNP, an A-G substitution at nucleotide position þ 896, downstream of the cDNA start codon (Arbour et al., 2000) . This missense mutation leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene (Arbour et al., 2000) . SNP Asp299Gly was later shown to co-segregate with SNP Thr399Ile-also in the third exon of TLR4. Both SNPs are present in 10% of Caucasian populations and are reported to have a positive correlation with susceptibility to several infectious diseases (including gram-negative sepsis), atherosclerosis, asthma, malaria and also Helicobacter pylori-induced gastric cancer and its precursors (Mockenhaupt et al., 2006; Hold et al., 2007) . However, neither SNP is present in Asian populations. The SNPs disrupt the normal structure of the extracellular region of the TLR4 and are therefore hypothesized to decrease responsiveness to lipopolysaccharide (LPS) through alterations in binding. Furthermore, mutant TLR4-transfected THP-1 cell lines have been shown to elicit a decreased LPS-induced immune response resulting in lower levels of cytokine production, which subsequently increases the susceptibility of host to bacterial infection (Schroder and Schumann, 2005) . To date, 44 TLR4 SNPs have been identified; however, the TLR4 Asp299Gly remains the best described and studied in relation to association with disease risk and altered functionality of the gene. Systematic gene analysis of TLR4 SNPs revealed an association between the rare mutation G11481C in the 3 0 UTR region of TLR4 and increased risk of developing prostate cancer (Zheng et al., 2004) .
Toll-like receptor 5
SNPs in the TLR5 gene have been reported to be associated with numerous infectious diseases; however, for most of them, functionality and prevalence remain unknown. In silico analysis based on genetic database searching of the TLR5 gene sequence has revealed 18 polymorphisms, 13 of which are nonsense polymorphisms and 5 silent polymorphisms (Hawn et al., 2003) . Hawn et al.(2003) showed a frequent SNP at position þ 1174 (TLR5 þ 1174C/T) caused truncation of the TLR5 protein at amino acid position 392 (TLR5 Arg392stop). Carriers of the stop codon variant were shown to have severely impaired pro-inflammatory cytokine IL-6 production, and concluded these carriers may be more susceptible to flagellated bacterial infections.The polymorphism has been shown to be associated with increased susceptibility to fatal infectious Legionnaires disease but protective against inflammatory disease, such as systemic lupus erythematosus (Hawn et al., 2005) . As far as we know, polymorphisms in TLR5 are not associated with risk of cancer. Only a few studies have shown a positive correlation between SNPs in TLR9 and susceptibility to disease. A total of 20 different human TLR9 SNPs were identified by direct sequencing of 71 human subjects (Lazarus et al., 2002) . However, only four were found in the public dbSNP database, dbSNP ID TLR9 A-1923C (rs352144), TLR9 T-1486C (rs187084), TLR9 G1174A (rs352139) and TLR9 G2848A rs352140. These four SNPs are common in American, European and African-American populations (at a frequency of 10% or above in population controls). A SNP within TLR9 proximal promoter region, substituting tyrosine to cytosine at nucleotide position À1237, has been reported to be associated with increased risk to allergic asthma among an American-European cohort (Lazarus et al., 2003) . Five exploratory nested case-control disease association studies were performed to investigate the association between a haplotype genotype comprising T-1237C and a second TLR9 SNP A2848G in the coding region of the TLR9 gene and risk for myocardial infarction (MI), deep vein thrombosis and chronic obstructive pulmonary disease. Disappointingly, results from this study only showed the association between the T-1237C polymorphism and allergic asthma in the European-Americans population, but no association were found with the four other diseases (Lazarus et al., 2003) . Berghofer et al. (2005) further investigated the association between common TLR9 SNPs, with atopy-related phenotypes. They first examined the frequency of the five most frequent TLR9 SNPs, A-1923C, T-1486C, T-1237C, G1174A and G2848A, and common TLR9 haplotypes in a large European population. Furthermore, these common SNPs and haplotypes were investigated for the association with the functionality of TLR9-induced IFN-g production. Results from this study showed that the common TLR9 SNPs and haplotypes were not associated with CpG-DNA-induced IFN-g production and were unlikely to be associated with the development of allergy. Thus, these SNPs in TLR9 are not the major risk factor for atopy (Berghofer et al., 2005) . Recently, Bouchud et al. (2007) analysed the association between 28 TLR9 polymorphisms and HIV-infection in a Swedish cohort. Results of this study indicated that SNP A1635G and G1174A which are in linkage disequilibrium were associated with rapid progressor HIV-1 phenotype. Although the À1237 promoter polymorphism has been shown to have an increased risk to several microbial-induced conditions, the functional effects remain unknown. In silico analysis shows that the SNP creates a putative nuclear factor-kappa B (NF-kB) binding site, which may be functionally relevant.
Specific examples of TLR polymorphisms and cancer

H. pylori-induced gastric cancer model
To illustrate the intricate interactions between host genes, microbial challenge and risk of malignancy, we first use the H. pylori-induced gastric cancer model. This is a superb example of host-bacterial interactions where the handling of the bacterial challenge in the stomach has a major impact on clinical outcome. The innate immune responses, including TLRs, play an essential role in the initial handling of the organism. The tone and direction of this interaction ultimately establishes the immune response against the bacterium and sets the scene for potential clinical outcomes that range from simple asymptomatic gastritis to more serious outcomes such as peptic ulcer disease and gastric cancer. H. pylori infection elicits a powerful humoral and cell-mediated immune response that causes inflammation in the gastric mucosa. The mediators of this inflammatory response belong to the two main arms of the immune system, namely adaptive and innate immunity.
Gastric cancer and H. pylori infection Gastric cancer remains a major health problem despite the recent decline in the incidence of this malignancy in the developed world. The global burden is shifting from the developed to the developing world and around 1.1 million new cases are expected in the year 2010 (Parkin et al., 2005) . H. pylori infection is the most recognized aetiological risk factor for this malignancy (Suerbaum and Michetti, 2002) . H. pylori infection causes a chronic gastritis that is the precursor to all the pathophysiological abnormalities characteristic of gastric carcinogenesis (Peek and Blaser, 2002) . The most important of these abnormalities are severe corpus-predominant gastritis, gastric atrophy and hypochlorhydria, which develop as a direct result of the chronic inflammation induced by the infection (El-Omar et al., 1997; Macarthur et al., 2004) . It is important to appreciate however that this so-called 'gastric cancer phenotype' is a relatively rare outcome whilst the overwhelming majority of infected subject worldwide do not develop any significant clinical disease. This second 'benign' phenotype is characterized by a mild mixed gastritis pattern that has little impact on gastric physiology, particularly on gastric acid secretion. Finally, there is a third phenotype, the so-called 'duodenal ulcer phenotype', which is characterized by an antrum-predominant gastritis, high gastric acid secretion and an increased risk of developing duodenal ulcers (El-Omar et al., 1995) . The latter group account for a variable percentage of infected subjects and are relatively common in the West (up to 15%) and rare in the East. Furthermore, subjects who develop duodenal ulcers are actually protected from developing gastric cancer, suggesting that the two outcomes are mutually exclusive (Hansson et al., 1996) . It is clear therefore that H. pylori infection can lead to several divergent clinical outcomes. Explaining this apparent paradox is essential for understanding the pathogenesis of H. pylori-related disease in general and gastric cancer in particular. The last two decades have seen major advances in unravelling the contribution of bacterial virulence factors, environmental exposures and host genetic factors in the pathogenesis of H. pyloriinduced diseases.
Genetic polymorphisms of cytokines of the adaptive immune response clearly play an important role in the risk of H. pylori-induced gastric adenocarcinoma (ElOmar et al., 2000 (ElOmar et al., , 2003 Machado et al., 2003; El-Omar, 2006) . However, H. pylori is initially handled by the innate immune response and it is conceivable that functionally relevant polymorphisms in genes of this arm of the immune system could affect the magnitude and subsequent direction of the host's response against the infection. The majority of H. pylori cells do not invade the gastric mucosa but the inflammatory response against it is triggered through attachment of H. pylori to the gastric epithelia (Segal et al., 1997) . TLR4, the lipopolysaccharide (LPS) receptor, was initially identified as the potential signalling receptor for H. pylori on gastric epithelial cells (Su et al., 2003) . TLR4 belongs to a family of pattern recognition receptors, of which there are currently 11 members, that activate pro-inflammatory signalling pathways in response to microbes or pathogen-associated molecular patterns (Pasare and Medzhitov, 2005) . TLR4, in conjunction with CD14 and MD-2, transduces signals through MyD88, Toll/IL-1 receptor domain and TRAF6. This promotes transcription of genes, which are involved in immune activation including the transcription factor NF-kB and also MAP kinase pathways (Takeda and Akira, 2005) .
Arbour et al. (2000) described a functional polymorphism at position þ 896 in exon 4 of the TLR4 gene (dbSNP ID: rs4986790). This A>G transition results in replacement of a conserved aspartic acid residue with glycine at amino acid 299 (Asp299Gly), and alteration in the extracellular domain of the TLR4 receptor. This renders carriers hyporesponsive to LPS challenge by either disrupting transport of TLR4 to the cell membrane or by impairing ligand binding or protein interactions (Arbour et al., 2000) . The mutation has been associated with a variety of inflammatory and infectious conditions including atherosclerosis, MI, inflammatory bowel disease and septic shock (Kiechl et al., 2002; Lorenz et al., 2002; Franchimont et al., 2004) . Recent work demonstrates that defective signalling through the TLR4 receptor ultimately leads to an exaggerated inflammatory response with severe tissue destruction, even though the initial immune response may be blunted. This is due to inadequate production of IL-10-secreting type 1 regulatory cells (Higgins et al., 2003) .
We hypothesized that the TLR4 þ 896A>G polymorphism would be associated with an exaggerated and destructive chronic inflammatory phenotype in H. pylori infected subjects. This phenotype would be characterized by gastric atrophy and hypochlorhydria, the hallmarks of subsequent increased risk of gastric cancer. We further hypothesized that the same polymorphism might increase the risk of gastric cancer itself. We proceeded to test the effect of this polymorphism on the H. pyloriinduced gastric phenotype and the risk of developing pre-malignant and malignant outcomes. We assessed associations with pre-malignant gastric changes in relatives of gastric cancer patients, including those with hypochlorhydria and gastric atrophy. We also genotyped two independent Caucasian population-based case-control studies of upper gastrointestinal tract cancer, initially in 312 non-cardia gastric cancer cases and 419 controls and then in 184 non-cardia gastric cancers, 123 cardia cancers, 159 oesophageal cancers and 211 frequencymatched controls. TLR4 þ 896G carriers had a 7.7-fold (95% CI, 1.6-37.6) increased odds ratio (OR) for hypochlorhydria; the polymorphism was not associated with gastric acid output in the absence of H. pylori infection. Carriers also had significantly more severe gastric atrophy and inflammation (Hold et al., 2007) . Sixteen percent of gastric cancer patients in the initial study and 15% of the non-cardia gastric cancer patients in the replication study had one or two TLR4 variant alleles vs 8% of both control populations (combined OR ¼ 2.4; 95% CI ¼ 1.6-3.4) (Hold et al., 2007) . In contrast, prevalence of TLR4 þ 896G was not significantly increased in oesophageal squamous cell (2%, OR ¼ 0.4) or adenocarcinoma (9%, OR ¼ 0.8) or gastric cardia cancer (11%, OR ¼ 1.2) (Hold et al., 2007) .
The association of TLR4 þ 896A>G polymorphism with both gastric cancer and its precursor lesions implies that it is relevant to the entire multistage process of gastric carcinogenesis, which starts with H. pylori colonization of the gastric mucosa. Subjects with this polymorphism have an increased risk of severe inflammation and subsequently, development of hypochlorhydria and gastric atrophy, which are regarded as the most important pre-cancerous abnormalities. This severe inflammation is initiated by H. pylori infection but it is entirely feasible that subsequent co-colonization of an achlorhydric stomach by a variety of other bacteria may sustain and enhance the microbial inflammatory stimulus and continue to drive the carcinogenic process. Evidence supporting this concept comes from the work of Sanduleanu et al. (2001) who showed that pharmacological inhibition of acid secretion was associated with a higher prevalence of non-H. pylori bacteria. Furthermore, the simultaneous presence of H. pylori and non-H. pylori bacteria was associated with a markedly increased risk of atrophic gastritis, and with higher circulating levels of IL-1b and IL-8. Supportive evidence also comes from animal studies where hypochlorhydria was induced in mice either genetically (GÀ/À gastrindeficient mice) or pharmacologically (administration of omeprazole). Zavros et al. (2002) found that genetic or chemical hypochlorhydria predisposes the stomach to bacterial overgrowth resulting in inflammation, which was not present in the wild type mice or those not treated with an acid inhibitor.
We propose that subjects with a pro-inflammatory genetic makeup based on a combination of markers from the adaptive immune response (for example, IL-1b, tumour necrosis factor a (TNF-a), IL-10, IL-8) and the innate immune response (for example, TLR4), respond to H. pylori infection by creating an environment within the stomach that is chronically inflamed and with reduced acidity. This environment is conducive to the growth of other bacteria within the gastric milieu, leading to sustained inflammation and oxidative/genotoxic stress. Subjects with the same pro-inflammatory polymorphisms may respond in the same exaggerated manner to these non-H. pylori bacteria, thus maintaining the pro-neoplastic drive. This may explain why H. pylori is not required in the latter stages of gastric carcinogenesis and why it is often absent from gastric tumour tissue.
The potential mechanism by which the TLR-4 polymorphism increases the risk of gastric cancer and its precursors is intriguing and may lie in the nature of the host's overall response to the H. pylori LPS attack. Failure to handle the invasion by appropriately recognizing and activating the necessary pathways may lead to an imbalance of pro-and anti-inflammatory mediators. A very elegant demonstration of this phenomenon was recently reported by Higgins et al. (2003) . The authors infected TLR4 defective C3H/HeJ mice and their wild-type counterparts (C3H/HeN) with an aerosol of Bordetella pertussis (a gram-negative bacterium that causes whooping cough) and monitored the course of the infection and its consequences over several weeks. The course of the infection was more severe in the TLR4-defective than the wild-type mice and this was associated with enhanced inflammatory cytokine production, cellular infiltration and severe pathological changes in the lungs. Most interestingly, Higgins et al. showed that signalling through TLR4 in response to bacterial infection activated IL-10 production, which promoted IL-10-producing T cells and controlled inflammatory pathology during infection in normal, but not TLR4-defective mice. It is therefore likely that the severe tissue damage observed in the TLR4 defective mice was due to the deficiency of the anti-inflammatory IL-10, which in turn accentuated the pro-inflammatory destructive tissue response.
TLRs have the ability to recognize pathogens or pathogen-derived products and initiate signalling events leading to activation of innate host defences (Pasare and Medzhitov, 2005) . Signalling by TLRs induces antimicrobial genes and pro-inflammatory cytokines and chemokines and leads to acute inflammatory responses (Janeway and Medzhitov, 2002) . Signals that recruit neutrophils and activated macrophages contribute to the killing of microbes, but more importantly, they also lead to activation of adaptive immune responses. In the case of H. pylori infection, it is generally accepted that TLRs, in addition to other receptors such as Nod1 (Viala et al., 2004) , are at least partly involved in the initial recognition of the bacterium. However, there has been much debate about whether H. pylori's LPS is recognized by TLR4 or TLR2 (whose natural ligands include peptidoglycan, lipopeptides and lipoteichoic acid from gram-positive bacteria). In particular, there is controversy about whether gastric epithelial cells express TLR4 and whether the LPS of H. pylori is involved in the signalling pathways leading to production of proinflammatory cytokines. In terms of expression, there is now strong evidence that gastric epithelial cells express TLR4, as well as other TLRs. Using immunoblot analysis and immunofluorescence histochemistry with an anti-TLR4 antibody, Kawahara et al. (2001a, b) showed that guinea pig gastric pit cells possessed significant amounts of TLR4 protein preferentially on the plasma membrane. Furthermore, H. pylori LPS activated NF-kB in association with the expression of cyclooxygenase II and TNF-a transcripts. They concluded that TLR4 of gastric pit cells plays an essential role in initiating an inflammatory response against H. pylori. More importantly, the localization of TLR4, and other TLRs, has recently been studied in the noninflamed human gastric mucosa and in patients with H. pylori infection. Using confocal microscopy, Schmausser et al. (2004) confirmed that TLR4, TLR5 and TLR9 were expressed by non-inflamed gastric epithelium and in chronic active H. pylori-induced gastritis. TLR4 was expressed at the apical and basolateral pole of the gastric surface epithelium, and indeed in H. pylori gastritis, the bacterium was directly attached to the TLR4 receptor expressed at the apical epithelial pole.
The findings by Schmausser et al. (2004) contradict earlier findings by Backhed et al. (2003) . The latter group examined expression of TLR2, TLR4 and TLR5 in antral biopsies from 20 subjects (six infected with cagA-positive strains, nine with cagA-negative strains and five uninfected). The three TLRs were expressed in all 20 biopsy specimens but interestingly, primary antral cell preparations from 9 donors failed to show any expression of TLR4 message. To test whether H. pylori is recognized via the TLR4 signalling pathway at all, the authors infected the TLR4-expressing and LPS-responsive bladder epithelial cell line T24 with a wild-type strain of H. pylori. They showed that only the wild-type strains and not the Dcag PAI and virB10 mutants induced IL-8 production. The authors concluded that gastric mucosal recognition of H. pylori is independent of TLR4. Using cancer cell line systems, Smith et al. (2003) investigated whether TLR2, TLR4 and TLR5 were required for NF-kB activation and induction of chemokines mRNA expression. They showed that gastric epithelial cells recognize and respond to H. pylori infection at least in part via TLR2 and TLR5 and that the H. pylori LPS is a TLR2 and not a TLR4 agonist. Smith et al. used LPS from a heavily passaged H. pylori laboratory strain (26695), and it is conceivable that this may have affected their results. In contrast, Mandell et al. (2004) using an identical experimental design to Smith et al., but with LPS derived from clinical isolates, showed that the cytokine-inducing activity of H. pylori LPS was mediated by TLR4. Intriguingly however, the response to whole Helicobacter bacteria was mediated not by TLR4 but rather by TLR2. In any case, whether TLR4 is crucial for gastric epithelial recognition of H. pylori or otherwise, the fact remains that the bacteria are eventually recognized, whether by epithelial cells or inflammatory cells, and it appears that genetic polymorphisms in the TLR4 gene have an important impact on this process. Our findings should act as a stimulus for further research into the role that TLRs and other mediators of the innate immune response play in H. pylori-related disease and other gram-negative bacterial infections.
Polymorphisms in Toll-like receptors and prostate cancer
Prostate cancer is the commonest non-skin malignancy in men in the West, claiming the lives of 30 000 men per year in the USA (Jemal et al., 2005) . There has been an alarming increase in the incidence of this cancer worldwide. The pathogenesis of prostate cancer is complex but there is increasing interest in the role of chronic inflammation in this malignancy. Recently, a new hypothesis has been proposed for prostate carcinogenesis where chronic inflammation appears to be the major driving force; for an outstanding review see De Marza et al. (2007) . The aetiology of this chronic inflammation is varied and combines the effects of exposure to environmental factors (for example, infectious agents and dietary carcinogens) and hormonal imbalances. The combination leads to sustained injury of the prostate and to the development of chronic inflammation and regenerative 'risk factor' lesions, referred to as proliferative inflammatory atrophy (De Marzo et al., 1999 . To a great extent, this proposed pathogenesis mirrors that described for H. pylori-induced gastric cancer and it is quite likely that bacteria or microbial agents (either pathogenic or commensal), might be the crucial trigger for this chronic inflammation. As such, it came as no surprise that polymorphisms in the TLR genes were implicated in the risk of prostate cancer.
Recently, sequence variants in several TLR genes have been linked to prostate cancer risk, including TLR4 and the TLR1-6-10 gene cluster (see Table 1 ), (Zheng et al., 2004; Sun et al., 2005) . In the study by Zheng et al. (2004) which was set in Sweden (the CAPS study), a SNP in the 3 0 UTR region of TLR4 (11381G/C) was found to be associated with prostate cancer risk. Carriers of the GC or CC genotypes of this SNP had a 26% increased risk of prostate cancer, and a 39% increased risk of early-onset prostate cancer (before the age of 65 years), compared with men with the wild-type GG genotype. Sun et al. (2005) reported on the TLR1-6-10 cluster in prostate cancer patients in the same Swedish cohort. They identified an association of sequence variants in TLR1-6-10 with prostate cancer risk. The allele frequencies of 11 of the 17 SNPs examined in this gene cluster were statistically significantly different between case and control subjects (P ¼ 0.04-0.001), with ORs for variant allele carriers (homozygous or heterozygous) compared with wild-type allele carriers ranging from 1.20 (95% CI ¼ 1.00-1.43) to 1.38 (95% CI ¼ 1.12-1.70). The association studies reported by Sun et al. and Zheng et al. require biological validation, as the variants reported have no apparent functional consequences. Nonetheless, the exciting angle that these studies highlight is the association between genes involved in the innate immune response, chronic inflammation and microbial handling. This is a major leap forward in the understanding of this important malignancy.
Summary
TLRs are important members of the innate immune response that allow the host to protect itself against microbial danger and other harmful agents. Genetic variations in these genes have been shown to directly affect risk of infectious diseases, allergy, cardiovascular disease and more importantly cancer. The best examples of how these TLR genetic polymorphisms impact on risk of cancer are demonstrated in gastric and prostate cancer, two malignancies in which chronic inflammation is the underlying pathological event. In the former, the aetiological agent, namely H. pylori infection, is well established and the pathogenesis is very well understood. As a consequence, the prospects for defeating this major global killer are very real. In the case of prostate cancer, it appears that interest in the role of chronic inflammation and the potential aetiologies of this inflammation including infections are at last gaining mainstream recognition. This is excellent news for those concerned with reducing the burden of this alarmingly rising cancer. For both gastric and prostate cancer, the study of host genetics of the TLRs has contributed significantly to the understanding of the aetiology and the pathogenesis of the cancers. The next decade promises to be even more exciting and our hope is that more cancers would be re-examined with such a hypothesis driven approach.
